Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-Current Assets: 2014-2024

Historic Non-Current Assets for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $13.4 million.

  • Zevra Therapeutics' Non-Current Assets fell 51.14% to $45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year decrease of 51.14%. This contributed to the annual value of $13.4 million for FY2024, which is 22.94% up from last year.
  • Zevra Therapeutics' Non-Current Assets amounted to $13.4 million in FY2024, which was up 22.94% from $10.9 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Non-Current Assets ranged from a high of $22.5 million in FY2022 and a low of $2.8 million during FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $13.4 million (2024), whereas its average is $15.6 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Non-Current Assets soared by 532.65% in 2021, and later plummeted by 51.57% in 2023.
  • Zevra Therapeutics' Non-Current Assets (Yearly) stood at $2.8 million in 2020, then skyrocketed by 532.65% to $17.9 million in 2021, then grew by 25.84% to $22.5 million in 2022, then slumped by 51.57% to $10.9 million in 2023, then climbed by 22.94% to $13.4 million in 2024.